Wall Street Zen cut shares of Exagen (NASDAQ:XGN – Free Report) from a hold rating to a sell rating in a report published on Saturday morning,Wall Street Zen reports.
Several other analysts have also issued reports on the stock. TD Cowen upped their price target on shares of Exagen from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Exagen in a research note on Wednesday, November 4th. B. Riley Financial began coverage on Exagen in a report on Friday, September 11th. They issued a “buy” rating and a $12.00 price objective on the stock. Canaccord Genuity Group lowered their target price on Exagen from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, November 11th. Finally, BTIG Research reissued a “buy” rating and issued a $9.00 target price on shares of Exagen in a research note on Wednesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.88.
Get Our Latest Stock Analysis on XGN
Exagen Stock Down 8.7%
Shares of XGN opened at $3.77 on Friday. The company has a debt-to-equity ratio of 1.73, a quick ratio of 3.18 and a current ratio of 3.46. Exagen has a fifty-two week low of $2.59 and a fifty-two week high of $9.22. The firm has a 50 day moving average price of $7.63 and a 200-day moving average price of $5.13.
Exagen (NASDAQ:XGN – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Exagen had a negative net margin of 25.14% and a negative return on equity of 125.60%. The business had revenue of $18.42 million during the quarter, compared to analysts’ expectations of $18.34 million. As a group, research analysts forecast that Exagen will post -0.71 earnings per share for the current year.
Insiders Place Their Bets
In other Exagen news, CEO John Aballi sold 34,294 shares of the firm’s stock in a transaction on Friday, October 16th. The shares were sold at an average price of $7.87, for a total value of $269,893.78. Following the sale, the chief executive officer owned 805,540 shares of the company’s stock, valued at $6,339,599.80. This trade represents a 4.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Jorey Chernett sold 58,068 shares of the firm’s stock in a transaction on Friday, November 13th. The stock was sold at an average price of $4.08, for a total transaction of $236,917.44. Following the completion of the sale, the insider directly owned 2,529,436 shares in the company, valued at approximately $10,320,098.88. This trade represents a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have purchased 100,900 shares of company stock valued at $568,660 and have sold 213,063 shares valued at $1,084,856. Corporate insiders own 10.40% of the company’s stock.
Hedge Funds Weigh In On Exagen
Hedge funds and other institutional investors have recently modified their holdings of the company. Corient Private Wealth LP purchased a new stake in shares of Exagen during the second quarter worth about $52,000. Penbrook Management LLC bought a new stake in shares of Exagen in the third quarter worth about $92,000. Calamos Advisors LLC purchased a new position in Exagen during the 3rd quarter valued at about $94,000. Bank of New York Mellon Corp purchased a new position in Exagen during the 2nd quarter valued at about $97,000. Finally, Empowered Funds LLC purchased a new position in Exagen during the 3rd quarter valued at about $198,000. 75.25% of the stock is owned by institutional investors.
Exagen Company Profile
Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.
See Also
- Five stocks we like better than Exagen
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
